Gabriel L Sica

Summary

Affiliation: Emory University
Country: USA

Publications

  1. doi request reprint Lung cancer staging: pathology issues
    Gabriel L Sica
    Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, Georgia, USA
    Semin Diagn Pathol 29:116-26. 2012
  2. doi request reprint Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variables
    Madhusmita Behera
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
    Clin Lung Cancer 14:128-38. 2013
  3. pmc Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer
    Rui Li
    Department of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute, Emory University, Atlanta, Georgia, United States of America
    PLoS ONE 8:e74670. 2013

Collaborators

Detail Information

Publications3

  1. doi request reprint Lung cancer staging: pathology issues
    Gabriel L Sica
    Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, Georgia, USA
    Semin Diagn Pathol 29:116-26. 2012
    ....
  2. doi request reprint Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variables
    Madhusmita Behera
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
    Clin Lung Cancer 14:128-38. 2013
    ..Lung cancer is the leading cause of cancer-related mortality. Understanding patient attributes that enhance survival and predict recurrence is necessary to individualize treatment options...
  3. pmc Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer
    Rui Li
    Department of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute, Emory University, Atlanta, Georgia, United States of America
    PLoS ONE 8:e74670. 2013
    ..Based on our findings, treatment with erlotinib combined with niclosamide may offer an effective therapeutic approach to improve the prognosis of head and neck cancer. ..